THE DONOR DEPENDENT IMMUNE MODULATORY POTENTIAL OF MESENCHYMAL STROML CELL PREPARATIONS CAN BE PREDICTED BY GALECTIN-9

被引：0
|
作者：
Ungerer, C. [1 ,2 ]
Quade-Lyssy, P. [1 ]
Radeke, H. [3 ]
Henschler, R. [4 ]
Seifried, E. [1 ]
Schuettrumpf, J. [1 ,2 ]
机构：
[1] DRK Blood Donor Serv, Frankfurt, Germany
[2] Biotest, Dreieich, Germany
[3] Pharmazentrum Frankfurt, Frankfurt, Germany
[4] Maximilian Univ Munich, Munich, Germany
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P995
引用
收藏
页码：411 / 411
页数：1
相关论文
共 33 条
  • [21] Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors
    Komita, Hideo
    Koido, Shigeo
    Hayashi, Kazumi
    Kan, Shin
    Ito, Masaki
    Kamata, Yuko
    Suzuki, Masafumi
    Homma, Sadamu
    ONCOLOGY REPORTS, 2015, 34 (04) : 2099 - 2105
  • [22] Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner
    Oomizu, Souichi
    Arikawa, Tomohiro
    Niki, Toshiro
    Kadowaki, Takeshi
    Ueno, Masaki
    Nishi, Nozomu
    Yamauchi, Akira
    Hirashima, Mitsuomi
    CLINICAL IMMUNOLOGY, 2012, 143 (01) : 51 - 58
  • [23] The Dual Role of the NFATc2/galectin-9 Axis in Modulating Tumor-Initiating Cell Phenotypes and Immune Suppression in Lung Adenocarcinoma
    Xiao, Zhi-Jie
    Wang, Si-Qi
    Chen, Jun-Jiang
    Li, Yun
    Jiang, Yuchen
    Tin, Vicky Pui-Chi
    Liu, Jia
    Hu, Huiyi
    Wong, Maria Pik
    Pan, Yihang
    Yam, Judy Wai Ping
    ADVANCED SCIENCE, 2024, 11 (20)
  • [24] Galectin-9 expression on tumour- associated immune cells is associated with favourable clinicopathological features and better outcomes in oral squamous cell carcinoma
    Peksa, Rafal
    Kunc, Michal
    Piatek, Michal
    Radecka, Barbara S.
    Jereczek-Fossa, Barbara Alicja
    Starzynska, Anna
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (01): : 22 - 27
  • [25] Delayed ischaemic preconditioning in the presence of galectin-9 protects against renal ischaemic injury through a regulatory T-cell dependent mechanism
    Zhang, Bing-Ying
    Fang, Yi
    Jiao, Xiao-Yan
    Wu, Sheng
    Cai, Jie-Ru
    Zou, Jian-Zhou
    Ding, Xiao-Qiang
    NEPHROLOGY, 2016, 21 (10) : 828 - 834
  • [26] Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients
    Liu, Zhao-Yun
    Meng, Nan-Hao
    Cao, Pan-Pan
    Jia, Yue
    Wang, Hao
    Zhang, Yun-He
    Liu, Hui
    Fu, Rong
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (03):
  • [27] PAK1-MEDIATED IMMUNE ESCAPE CONFERRED BY REGULATION OF IMMUNE CELLS DUE TO TUMOR-ASSOCIATED NEUTROPHILS RECRUITMENT AND GALECTIN-9 SECRETION IN RENAL CELL CARCINOMA
    Zhu, Yu
    Fu, Hangcheng
    Ye, Dingwei
    JOURNAL OF UROLOGY, 2020, 203 : E237 - E238
  • [28] Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells
    Veenstra, Rachelle G.
    Taylor, Patricia A.
    Zhou, Qing
    Panoskaltsis-Mortari, Angela
    Hirashima, Mitsuomi
    Flynn, Ryan
    Liu, Derek
    Anderson, Ana C.
    Strom, Terry B.
    Kuchroo, Vijay K.
    Blazar, Bruce R.
    BLOOD, 2012, 120 (03) : 682 - 690
  • [29] A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance
    Nina Ketterl
    Gabriele Brachtl
    Cornelia Schuh
    Karen Bieback
    Katharina Schallmoser
    Andreas Reinisch
    Dirk Strunk
    Stem Cell Research & Therapy, 6
  • [30] a Galectin-9 as a Predictive Marker for the Onset of Immune Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia
    Mohammed, Tareg Omer
    Chagan-Yasutan, Haorile
    Ashino, Yugo
    Nakayama, Wakana
    Takahashi, Yayoi
    Shimomura, Taizo
    Fujimoto, Tetsuhiro
    Watanabe, Yuko
    Niki, Toshiro
    Suzushima, Hitoshi
    Hattori, Toshio
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2017, 241 (03): : 201 - 208
1234